Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 15/20 | 1.00 |
| ▸ | APOB | P04114 | 14/20 | 1.00 |
| ▸ | SMO | Q99835 | 8/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038523 | 1.00 | MTTP (1.00) | MTTPAPOBSMO | |
| SCHEMBL10205353 | 1.00 | MTTP (1.00) | MTTPAPOBSMO | |
| SCHEMBL6196022 | 0.93 | MTTP (0.87) | MTTPAPOBSMO | |
| SCHEMBL13591624 | 0.92 | MTTP (0.85) | MTTPAPOBSMO | |
| SCHEMBL5961560 | 0.92 | SMO (0.85) | MTTPAPOBSMO | |
| SCHEMBL13591618 | 0.89 | SMO (0.82) | MTTPAPOBSMO | |
| SCHEMBL7035865 | 0.89 | SMO (0.79) | MTTPAPOBSMO | |
| SCHEMBL6198990 | 0.87 | SMO (0.78) | MTTPAPOBSMO | |
| SCHEMBL6196040 | 0.87 | SMO (0.78) | MTTPAPOBSMO | |
| SCHEMBL6200891 | 0.87 | SMO (0.78) | MTTPAPOBSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008090198-A1 | USE OF MTP INHIBITORS FOR INCREASING LEVELS OF SATIETY HORMONES | JANSSEN PHARMACEUTICA NV (BE) | 2008-07-31 | — | — | WO | claimed |
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-28 | — | — | US | claimed |
| WO-2008090198-A1 | USE OF MTP INHIBITORS FOR INCREASING LEVELS OF SATIETY HORMONES | JANSSEN PHARMACEUTICA NV (BE) | 2008-07-31 | — | — | WO | disclosed |
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | APOB, LIPC, MTPN | MTTP 9/4885APOB 1/4885SMO 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.